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Abstract: Objective: to examine the extent of effect vitamin D in Multiple Sclerosis (MS) on pathology 
and symptoms. Methods: A literature search was performed in November 2018 (CRD42018103615). 
Eligibility criteria: randomised control trials in English from 2012 to 2018; a clinical diagnosis of MS; 
interventions containing vitamin D supplementation (vitamin D3 or calcitriol) in disease activity 
compared to a control/placebo; improvement in: serum 25(OH)D, relapse rates, disability status by 
Expanded Disability Status Scale (EDSS) scores, cytokine profile, quality of life, mobility, T2 lesion 
load and new T2 or T1 Gd enhancing lesions, safety and adverse effects. Risk of bias was evaluated. 
Results: Ten studies were selected. The study size ranged from 40 to 94 people. All studies evaluated 
the use of vitamin D supplementation (ranging from 10 to 98,000 IU), comparing to a placebo or low 
dose vitamin D. The duration of the intervention ranged from 12 to 96 weeks. One trial found a 
significant effect on EDSS score, three demonstrated a significant change in serum cytokines level, one 
found benefits to current enhancing lesions and three studies evaluating the safety and tolerability of 
vitamin D reported no serious adverse events. Disease measures improved to a greater extent overall 
in those with lower baseline serum 25(OH)D levels. Conclusions: As shown in 3 out of 10 studies, 
improvement in disease measures may be more apparent in those with lower baseline vitami n D 
levels. 
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1. Introduction 
There is increasing evidence suggesting that specific environmental factors, such as exposure to 
infectious agents, smoking, poor diet and inadequate levels of vitamin D can influence the disease 
course of multiple sclerosis (MS) [1]. Adequate vitamin D status is documented as associated with 
reduced prevalence, activity and progression of disease in MS, and therefore high intake of vitamin D 
may be a useful addition to standard treatment [2]. Numerous observational studies invest igating 
variations in sunlight exposure, latitude and diet have supported the correlation between a high serum 
concentration of vitamin D and reduced severity of the disease course in established MS [3] [4]. 
Epidemiologic and experimental studies investigating the effectiveness of vitamin D 
supplementation in MS have shown that low serum vitamin D levels may exacerbate MS symptoms 
and therefore are associated with higher relapse rates, new lesions, and greater degree of disability[5] 
[6] [7] [8] [9]. Although there has been much research performed into the role of vitamin D in MS risk 
and progression, due to heterogeneity of study designs, there have been conflicting results. For 
example, baseline serum 25(OH)D levels often differ between studies. Reviews on the topic have thus 
far been inconclusive and are mainly focused on the role of vitamin D and risk of developing MS, rather 
than the outcomes after diagnosis [7]. The only two other systematic reviews to date on vitamin D for 
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the clinical efficiency of MS did not use the full range of terms for vitamin D nor wa s bias assessed [10] 
and didn’t assess cytokine outcomes nor looked at the effects of baseline Vitamin D levels on outcomes 
[11]. The aim of this review is to assess the evidence from existing randomised controlled trials for the 
clinical effectiveness of vitamin D supplementation compared to placebo supplement ation in the 
disease and symptom management of people with MS as measured by: improvement in: serum 
25(OH)D, relapse rates, disability status by Expanded Disability Status Scale (EDSS) scores, cytokine 
profile, quality of life, mobility, T2 lesion load and new T2 or T1 Gd enhancing lesions, safety , and 
adverse effects. 
2. Methods 
The systematic review was registered in PROSPERO (CRD42018103615). A literature search was 
performed in November 2018. Table 1 shows the search terms and number of hits for each database. 
Reference lists were hand searched for additional papers. Twenty percent of abstracts and papers were 
checked by a second reviewer. 
Table 1. Key search databases and search terms. 
Database 
Searched 
Search Terms Used 
Number of 
Results 
Date of 
Search 
PubMed 
• “Multiple Sclerosis” or “MS” 
• AND 
• “vitamin D supplementation” OR “vitamin 
D” OR “cholecalciferol” OR “ergocalciferol” OR 
“calcitrol” 
215 01/11/2017 
Web of 
Science 
• As above 197 04/11/2017 
CINAHL • As above 19 12/11/2017 
Science 
Direct 
• As above 354 12/11/2017 
Total  785  
Studies were included if they met each of the following criteria: A clinical diagnosis of MS; Direct 
relevance of vitamin D supplementation on the management of MS compared to a low dose vitamin D 
or a placebo supplement; Primary outcome measurements in one or more of: serum 25(OH)D, relapse 
rates, disability status by EDSS scores, cytokine profile, quality of life, mobility, T2 lesion load and new 
T2 or T1 Gd enhancing lesions, safety and adverse effects; Randomised control trial  (RCT) with a control 
and intervention group; Published from 2012 and in English; The published data available in full text; 
Only human randomised controlled clinical trials. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
were followed and the flow diagram is presented in Figure 1. Bias was assessed using the RoB 2.0 tool 
at a study level. Data were extracted by one reviewer, and a selection of excluded abstracts and all full 
papers, and included papers were confirmed by a second reviewer. 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram 
reporting the number of records identified, included and exclude through the different phases of a 
systematic review. 
3. Results 
Out of 785 studies, ten RCTs were identified as eligible for this review after the application of the 
inclusion and exclusion criteria. The information from each selected study was extracted, and detailed 
characteristics are shown in Table 2. 
3.1. Bias 
All studies were considered to have a low risk of bias and therefore systematic error was unlikely 
and there was no threat to validity. 
3.2. General Characteristics 
The studies reviewed in this report were all double-blind RCTs that focused on the role of vitamin 
D supplementation in the management of people with MS. Country of origin is shown in Table 2.  
Inclusion and exclusion criteria, in addition to other demographic information is shown in Table 3.  
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3.3. Participants 
The studies size ranged from 40 to 94 people with MS. In these ten studies, there was a total of 627 
adult participants (463 female and 164 male). Food intake of vitamin D and smoking status were not 
reported in any of the RCTs. 
3.4. Study Objectives 
Seven studies looked at the effect of vitamin D on immunological and inflammatory measures [12] 
[13] [14] [15] [16] [17] [18]. Outcomes related to functional ability were assessed in two studies[19] [20] 
and relapse rate was assessed in four studies[19] [21] [20] [12]. Disability and/or disease progression 
was assessed in five studies [12] [19] [20] [21] [18]and safety and tolerability of vitamin D 
supplementation was sought in four[12] [13] [20] [21]. The studies by[16] and [18], by [15]and [19] and 
by [14] and [20]were based on the same trial however measured different outcomes and as such were 
treated in this review as separate studies. 
3.5. Interventions 
The intervention dose varied across studies. All studies evaluated the use of vitamin D 
supplements of various doses (ranging from 10 to 98,000 IU), frequency (usually delivered weekly) and 
formulation (vitamin D3 and calcitriol). Most studies (n = 9) reported concomitant immunomodulatory 
therapy, often interferon-β as well as different requirements relating to vitamin D and calcium 
supplementation that were used at baseline. The duration of the vitamin D interventions varied 
between studies, ranging from 12 to 96 weeks. The included studies (n = 8) compared vitamin D 
supplementation (321 participants) to placebo (264 participants) or versus low dose of vitamin D (n = 
2; 42 participants). A variety of clinical and biochemical outcome measures were assessed at the baseline 
and the end of the study for intervention and control groups. 
3.6. Serum 25(OH)D levels 
Nine of ten studies in this review measured the serum 25(OH)D concentration for both 
intervention and control group (low dose vitamin D) as an outcome parameter (Table 4). Across studies, 
mean improvements in cytokine profile or EDSS were seen for those with low baseline plasma Vitamin 
D levels (n = 3). Key findings and significance are shown in Table 5. 
3.7. Immunologic Markers 
Seven of the ten studies in the review used change in serum cytokines level as an outcome 
parameter with mixed results found and large heterogeneity in markers assessed across studies. Best 
support was found for Ashtari et al. [16]and Sotirchos et al. [13] in which significant benefits were seen 
in the high dose Vitamin D groups on IL-10, and on IL-17+CD4+T and CD4+T cells these were also the 
studies where baseline vitamin D levels were lower than normal. 
Golan et al. [12] reported a significant increase in serum IL-17 concentration in people allocated to 
the low-dose vitamin D from a mean of 4.01 to 9.14 pg/mL at 48 weeks (P = 0.037) and a heterogeneous 
IL-17 response was observed in the high-dose vitamin D group. Therefore, there was a decrease and 
thus a beneficial change in 40% of participants and increase and negative change in 45% of participants 
after 3 months while 15% had IL-17 levels below the detection threshold at both time points. Aivo et al. 
[14]detected a significant increase in LAP (TGF-β) levels in the vitamin D arm after 48 weeks from a 
mean of 47 to 55 pg/mL (P = 0.02), while in those receiving placebo, this level increased but these 
changes were not significant (P = 0.173). Moreover, no significant difference in other cytokines 
concentration was reported in either group. Ashtari et al. [16]found that serum IL-10 concentration 
changed significantly in people receiving vitamin D for 12 weeks (P = 0.015) from a median of 12.58 to 
13.76 pg/mL. Rosjo et al. [15] indicated no significant differences from baseline values for any of the 
inflammation markers between those receiving vitamin D or placebo after 96 weeks of treatment. 
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Additionally, people with MS on immunomodulatory treatment (mostly consisting of IFN-b) were 
observed to have higher mean baseline levels of inflammation markers (IL-1Ra and CXCL16) compared 
to those not on therapy. However, there was no clear correlation between vitamin D supplementation 
and immunomodulatory treatment and its influence on the inflammation markers. Toghianifar et al. 
[18] showed that the proportion of cells including: nTreg, iTreg, Breg, IL4+ Th cells, IL5, and LAP 
(TGFβ) was not affected by a high-dose vitamin D supplementation. No difference in IL-17 levels 
between those who received vitamin D, and those who received placebo were observed at 12 weeks. 
Muris et al. [17] found no beneficial effects of a high-dose vitamin D supplementation on the circulating 
regulatory immune cell compartment (the fraction of Treg as the proportion of CD4+ T cells, nTregs, 
IL10+ Th cells) in those with MS. Sotirchos et al. [13]detected a significant change in the proportion of 
proinflammatory IL-17+CD4+T cells in the high-dose group (P = 0.016) from a mean of 9.32% to 5.62%, 
while no difference was observed in the low -dose group (P = 0.53). Moreover, a significant difference 
in IL-17+CD4+T cells in the high-dose group versus low-dose group was reported (p = 0.039). Greater 
reduction in the proportion of IFN-γ+CD4+ T cells and IFN-γ+IL-17+CD4+ T cells was noted in the high-
dose group versus the low-dose group but did not reach statistical significance (p = 0,12; p = 0.14). Also, 
a decreased proportion of effector memory CD4+T cell was noted after high -dose vitamin D 
supplementation from a mean of 40.56% to 30.69% (p = 0.021). The proportion of central memory and 
naive CD4+T cells increased significantly (p = 0.019; p = 0.043) in the high-dose group from a mean of 
50.07% to 60.96% and from 38.94% to 42.2%, respectively. 
3.8. Functional Measures 
Only one study assessed functional measures and although there were trends for improvements 
in the Vitamin D groups, there were no statistically significant changes between the intervention and 
placebo groups. Soilu-Hänninen et al. [20]demonstrated that vitamin D supplementation resulted in 
fewer new T2 lesions (a mean of 0.5 compared to a mean of 1.1 in the placebo group). However, the 
difference between vitamin D and placebo groups was not statistically significantly different (P = 0.286). 
Participants assigned to vitamin D demonstrated lower total number  of T1 Gd enhancing lesions (0.6 
to 0.1) while in the placebo group no change was reported and a higher decrease in T1 enhancing lesion 
volume in the vitamin D group (from 57 mm 3 to 3.1 mm3) compared with the placebo group (from 62 
mm3 to 29 mm3) but again the difference between the treatment groups was not statistically significant 
(P = 0.004, P = 0.320, respectively). There were no statistically significant differences between  the 
treatment groups in timed 10 foot tandem walk (TTW10; P = 0.076) (change from a mean of 11.7 to 9.7 
in the vitamin D group and from 9.6 to 11.2 in the placebo group) and T25FW (P = 0.932) at the end of 
the study (change from a mean of 6.0 to 5.3 in the vitamin D group and from 4.7 to 5.1 in the placebo 
group). 
3.9. Relapse Rate 
Four of ten studies in this review investigated the effect of supplementation with vitamin D on 
relapse rates, with no significant differences between the vitamin D and control groups. Kampman et 
al. [19] demonstrated that vitamin D supplementation resulted in an increase in annualised relapse rate 
(ARR, calculated as the total number of relapses experienced divided by the sum of participants and 
duration of follow-up) from 0.11 to 0.14, whereas in placebo group a decrease from 0.15 to 0.8 was 
reported. The difference between vitamin D and placebo group after 96 weeks was not significant (P = 
0.25). Shaygannejad et al. [21]documented that the relapse rate decreased significantly after 48 weeks 
from a mean of 1.04 to 0.32 in people who received vitamin D (P < 0.001) and from 1.04 to 0.40 in those 
who received placebo (P < 0.001). The study by Golan et al. [12] found an increase in ARR in patients 
with MS following the treatment with high-dose per day from 0.28 to 0.51 and decrease in the low -dose 
from 0.38 to 0.34 at week 48, but this difference was not statistically significant (P = 0.32). The study by 
Soilu-Hänninen et al. [20]found a decrease in ARR in both treatment arms: in people who received 
vitamin D from a mean of 0.49 to 0.26 and from 0.51 to 0.28 in those who received placebo, yet with no 
significant difference between groups. 
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Table 2. Characteristics of selected studies. 
Reference Participant Demographics 
Study Design, 
Duration and 
Country of Origin 
Intervention Outcome Measures 
[19] 
68 participants (48f, 20m) with MS; 
Age mean (range) in vitamin D group 
40 (21–50) and placebo 41 (26–50); 
BMI in vitamin D group 28 and 
placebo group 26 
Double-blind 
placebo- 
controlled RCT; 96 
weeks; Norway 
35 participants received supplementation with 
20,000 IU vitamin D3 (cholecalciferol)per week; 
comparator 33 participants received placebo 
Serum levels of 25(OH)D; ARR; EDSS; 
MSFC components; grip strength; FSS 
[21] 
50 participants (424f, 6m) with RRMS; 
Age mean (SD) in vitamin D 38.6 (8.4) 
and placebo 37.9 (7.9); No BMI 
Double-blind 
placebo-controlled 
RCT; 48 weeks; 
Iran 
25 participants received 0.25 μg/d of calcitriol for 2 
weeks and then 0.5 μg/d; comparator 25 
participants received placebo 
EDSS; relapse rate 
[12] 
45 participants (32f, 13m) with RRMS; 
Age mean in high-dose group 43.1 
(21.7–63.7) and in low-dose group 
43.6 (26.7–63.9); No BMI 
Double-blind 
placebo-controlled 
RCT; 48 weeks; 
Israel 
High-dose group, 24 participants received 75,000IU 
vitamin D3 solution every 3 weeks in addition to 
800 IU vitamin D3 per day (total 4370 IU); 
comparator low dose group, 21 participants 
received placebo every 3 weeks in addition to 800 
IU/d of vitamin D3 
Serum levels of 25(OH)D; FLS; serum 
calcium, PTH, cytokine levels (IL-17, IL-
10, and IFN-γ); EDSS, relapses, adverse 
events; QoL 
[14] 
59 participants (37f, 22m) with RRMS; 
Age mean (range) in vitamin D 38 
(22–53) and in placebo 35 (24–53); BMI 
24 kg/m2 
Double-blind RCT; 
48 weeks; Finland 
30 participants received 20,000 IU of vitamin D3 
(cholecalciferol) per week; comparator 29 
participants received placebo 
Serum levels of 25(OH)D; inflammatory 
cytokine: Serum concentrations of LAP 
(TGF-β); IFN-γ, IL-17A, IL-2, IL-10, IL-9, 
IL-22, IL-6, IL-13, IL-4, IL-5, IL-1β and 
TNF-α 
[16] 
89 participants (75f, 14m) with RRMS; 
Age mean (SD) in vitamin D group 
31.50 (7.60) and placebo 34.60 (10.12); 
No BMI 
Double-blind 
placebo-controlled 
RCT; 12 weeks; 
Iran 
High-dose vitamin D group, 44 participants 
received 50,000 IU of vitamin D3 every 5 days; 
comparator 45 participants received placebo 
Serum levels of 25(OH)D; serum calcium; 
serum interleukin 10 (IL-10) levels 
[15] 
68 participants (48f, 20m) with RRMS; 
Age mean (range) in vitamin D group 
40 (21–50) and placebo 41 (28–50); 
BMI vitamin D group 25.9 and 
placebo 26.5 
Double-blind 
placebo-controlled 
RCT; 96 weeks; 
Norway 
36 participants received 20,000 IU vitamin D3 per 
week; comparator 32 participants received placebo 
Serum 25(OH)D; 11 serum markers of 
inflammation, bone mineral density, 
clinical disease activity, disease 
progression: ALCAMd, CCL21e, 
CXCL16f, IL-1Rag, MMP-9h, OPGi, OPNj, 
PTX3k, sFRP3l, sTNF-R1m, TGF-b1n 
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[18] 
89 participants (75f, 14m) with RRMS; 
Age mean (SD) in vitamin D group 
31.50 (7.60) and placebo 34.60 (10.12); 
No BMI 
Double-blind 
placebo-controlled 
RCT; 12 weeks; 
Iran 
44 participants received oral vitamin D3 50,000 IU 
every 5 days; comparator 45 participants received 
placebo 
Serum levels of 25(OH)D, serum calcium, 
IL-17 
[17] 
53 participants (35f, 18m) with RRMS; 
Age mean (SD) in vitamin D group 
37.7 (7.2) and placebo 37.2 (9.6); BMI ≥ 
25 kg/m2  
Double-blind 
placebo-controlled 
RCT; 48 weeks; 
Netherlands 
30 participants received high-dose vitamin D3 
supplementation 7000 IU/d for 4 weeks, followed 
by 14,000 IU/d; comparator 23 participants 
received placebo 
Serum 25(OH)D; serum interleukin 10 (IL-
10) levels; cytokine expression of IL4, 
IFNγ, IL17, IL22, GMCSF and TNFα by 
CD3+ CD8− T lymphocytes 
[13] 
40 participants (28f, 12m) with RRMS; 
Age mean (SD) in high-dose group 
41.3 (8.1) and placebo 38.8 (8.8); No 
BMI 
Double-blind RCT; 
24 weeks; United 
States 
High-dose group, 19 participants received 10,000 
IU/d of cholecalciferol; comparator low-dose 
group, 21 participants received 400 IU/d of 
cholecalciferol 
Serum 25(OH)D levels; adverse events, 
relapses, IFN-γ+ IL-17+ CD4+ T cells 
[20] 
66 participants (41f, 15m) with RRMS; 
Age median (range) in vitamin D 
group 39 (22–53) and placebo 35 (24–
53); BMI median (range) in vitamin D 
group 24 (18–40) and placebo 24 (19–
38) 
Double-blind 
placebo controlled 
RCT; 48 weeks; 
Finland 
34 participants received oral vitamin D3 
(cholecalciferol) 20,000 IU once a week; comparator 
group 32 participants received placebo 
Serum levels of 25(OH)D; PTH level, T2 
BOD; total number of Gd enhancing T1 
lesions; new/enlarging T2 lesions; Gd 
enhancing lesion volume; MRI activity; 
ARR, EDSS, T25FW and TTW10 
ARR, annualised relapse rate; EDSS, Expanded Disability Status Scale; MSFC components, multiple  sclerosis functional composite including (25ft timed walk; 9-hole 
peg test (9-HPT), paced auditory serial addition test (PASAT)); FSS, fatigue severity scale ; FLS, flu-like symptoms; QoL, quality of life ; T2 BOD, T2 burden of disease; 
T25FW, timed 25 foot walk; TTW10, timed 10 foot tandem walk; BMI, body mass index; y, years; f, female; m, male; RCT, randomised controlled trial; SD, standard 
deviation; MS, multiple  sclerosis. RRMS, relapsing-remitting multiple  sclerosis; 25(OH)D, 25-hydroxy vitamin D. 
Table 3. Inclusion and exclusion criteria of reviewed studies. 
Study Age 
MS 
Diagnosis 
EDSS 
Score 
Serum 
25(OH)D 
Level 
Other Inclusion Criteria Exclusion Criteria 
[19] 
18–50 
years 
MS ≤4.5 n/a n/a 
Inability to walk 500 m or more; conditions or medication affecting 
bone health; pregnancy, lactating during the past 6 months; 
menopause; unwillingness to use contraception 
[21] 
15–60 
years 
RRMS ≤6 >40 ng/mL 
RRMS for 1–12 years, no relapse for at least one 
month; continue current medications 
SPMS and PPMS; other conditions; use of vitamin D supplements; 
pregnancy 
[12] 
≥18 
years 
RRMS <7 
 <75 nmol/L 
or (<30 
ng/mL) 
IFN-β therapy or those who continue to suffer 
from FLS beyond 4 months of treatment with 
IFN-β  
Abnormalities of vitamin D related hormonal system; use of 
medications that influence vitamin D metabolism; conditions of 
increased susceptibility to hype rcalcemia; pregnancy 
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[14] 
18–55 
years 
RRMS <5 
<85 nmol/L 
or (<34 
ng/mL) 
IFN-β therapy for at least 1month and no 
neutralizing antibodies; contraception; at least 
one relapse during the year prior the study 
and/or MRI activity defined as presence of Gd-
enhancing lesions on brain MRI 
Serum calcium > 2.6 mmol/L; other conditions; pregnancy; use of 
other immunomodulatory therapy than INFB-1β; allergy to 
cholecalciferol or peanuts; alcohol or drug abuse 
[16] 
18–55 
years 
RRMS <4 n/a 
No relapse 30 days before inclusion; negative 
β-HCG test for women; calcium < 11 mg/dL 
Pregnancy; lactation; other disease; receiving > 4000 IU of vitamin 
D, corticosteroids treatment in the previous 30 days; aspartate or 
alanine transaminase > 3xnormal values, ALP > 2.5xnormal values 
[15] 
18–50 
years 
RRMS <4.5 n/a n/a 
Disease or medication affecting bone health; menopause; 
pregnancy; lactation; nephrolithiasis 
[18] 
18–55 
years 
RRMS <4 <85 ng/mL 
No relapse 30 days prior to study day; negative 
β-HCG test for women; calcium < 11 mg/dL; no 
relapse during the study 
Pregnancy; lactation; other diseases; receiving >4000 IU of vitamin 
D, corticosteroids therapy in the previous 30 days; AST > 3xnormal 
values, ALP > 2.5xnormal values 
[17] 
18–50 
years 
RRMS ≤4 n/a 
No relapse within 30 days prior to study day; 
first clinical event occurring within 5 years 
prior to screening; have had at least one 
relapse, or one or more Gd-enhancing or new 
T2 MRI lesions within the 12 months; receiving 
IFNβ-1a > 90 days and <12 months 
Pregnancy or lactation; other diseases; use of corticosteroids or 
adrenocorticotrophic hormone within 30 days prior to SD1 
abnormalities of vitamin D-related hormonal system; use of 
medications that influence vitamin D metabolism; taking N400 IU 
(N10 μg) of vitamin D supplement daily 
[13] 
18–55 
years 
RRMS n/a 20–50 ng/mL 
No relapse within 30 days; serum creatinine 
>1.5 mg/dL 
Daily intake of vitamin D > 1000 IU or change of 
immunomodulatory therapy within the past 3 months, systemic 
glucocorticoid therapy; pregnancy, other condition 
[20] 
18–55 
years 
RRMS ≤5.0 <85 nmol/L 
IFNB-1b use for at least 1month; no 
neutralising antibodies to IFNβ, as measured 
by the indirect myxovirus A (MxA) test, using 
appropriate  contraceptive methods. 
Pregnancy; serum calcium >2.6 mmol/L; primary 
hyperparathyroidism; alcohol or drug abuse; use of 
immunomodulatory therapy other than IFNB-1b; known allergy to 
cholecalciferol or peanuts; therapy with digitalis, calcitonin, 
vitamin D3 analogues or vitamin D; any condition predisposing to 
hypercalcaemia; significant hypertension (blood pressure < 180/110 
mm Hg); hyperthyroidism or hypothyroidism in the year before 
the study began; a history of kidney stones in the previous 5 years; 
cardiac insufficiency or significant cardiac dysrhythmia; unstable 
ischaemic heart disease; depression; and inability to perform serial 
MRI scans. 
MS, multiple  sclerosis; RRMS, relapsing-remitting multiple  sclerosis; EDSS, expanded disability status scale; FLS, flue like symptoms; HCG, Human chorionic 
gonadotropin; ALP, Alkaline phosphatase; AST, Aspartate transaminase; SPMS, secondary progressive multiple  sclerosis; PPMS, primary progressive multiple  
sclerosis, SD1; study day 1; IFNβ, Interferon-β. 
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Table 4 Changes in serum 25(OH)D levels after intervention supplementation. 
References Within Group Differences Between Group Differences 
[19] 
Intervention: 20,000 IU of vitamin D significantly increased serum 25(OH)D levels from a 
mean of 55.56 to 123.17 nmol/L. Control: there was only a minor increase from 57.33 to 
61.80 nmol/L. 
Significant difference in serum levels of 25(OH)D after 96 weeks 
between the intervention and control groups (P < 0.001). 
[21] n/a n/a 
[12] 
Intervention: serum 25(OH)D levels significantly increased in a high-dose (4370 IU/d) 
groups from a mean of 48.2 to 122.6 nmol/L Control: low-dose (800 IU/d)  from 48 to 68 
nmol/L. 
Significantly higher serum 25(OH-D) levels were reported in 
high dose group compared to low-dose arm after 48 weeks (P < 
0.001). 
[14] 
Intervention: serum 25(OH)D levels increased significantly from a mean of 54 to 109 
nmol/L. Placebo: decreased from a mean of 55 to 51 nmol/L after 48 weeks. 
n/a 
[16] 
Intervention: Serum 25(OH)D levels rose from a median of 28.27 to 84.67 nmol/L. Placebo: 
fell from 39.6 to 28.66 nmol/L. 
A significant difference after 12 weeks between groups (P < 
0.001). 
[15] 
Intervention: serum levels of 25(OH)D significantly increased from 56 to 123nmol/L. 
Placebo: levels slightly increased from 57 to 63 nmol/L. 
A significant difference in serum levels after 96 weeks between 
groups (P < 0.001). 
[18] 
Intervention: serum 25(OH)D levels significantly increased from a median of 28.27 to 84.67 
ng/mL. Placebo: a decrease from 39.6 to 28.66 ng/mL. 
These differences were significant between groups after 12 
weeks (P < 0.001). 
[17] 
Intervention: serum 25(OH)D concentration increased significantly in the vitamin D group 
from 60 to 231 nmol/L. Placebo: changed to a lesser degree (54 to 60 nmol/L). 
The was a significant difference after 48 weeks between the 
groups (P < 0.001). 
[13] High dose: Mean change of 34.9 ng/mL. Low dose: mean change of 6.9 ng/mL 
A high dose of vitamin D resulted in significantly higher serum 
25(OH-D) levels versus low-dose after 24 weeks (P  <  0.00001). 
[20] 
Intervention: serum 25(OH)D levels increased from a mean of 54 to 110 nmol/L. Placebo: 
decreased from a mean of 56 to 50 nmol/L after 48 weeks 
A significant difference between groups (P < 0.001). 
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Table 5 Key findings of reviewed studies. 
Reference Key findings  Significance Conclusion 
[19] 1. Serum 25(OH)D level significantly increased in intervention group 
vs control 
2. ARR increased in intervention group vs control 
3. EDSS decreased in intervention group vs control 
4. MSFC components: 
    25ft timed walk decreased in intervention group vs control; 
    9-HPT increased in intervention group vs control; 
    PASAT increased in intervention vs control; 
5. Grip strength decreased in intervention group vs control; 
6. Fatigue increased in intervention group vs control 
1. P < 0.001 
2. P = 0.25 
3. P = 0.97 
4. 
P = 0.87; 
P = 0.35; 
P = 0.21 
 
5. P =0.76 
6. P =0.9 
Supplementation did not result in beneficial effects on 
the measured MS-related outcomes; no significant 
difference between groups in ARR, EDSS, MSFC 
components, grip strength or fatigue  
[21] 1. Relapse rate significantly decreased in intervention and control 
groups; no significant difference in relapse rate between the groups; 
2. EDSS unchanged in intervention group and increased in control 
1. P< 0.001;  
P < 0.001; 
P > 0.05; 
2. N/A; P < 0.01 
No significant differences in the EDSS score or relapse 
rate  between the vitamin D and control groups at the 
end of the study period; vitamin D supplementation at 
the doses used seems safe 
[12] 1. Serum 25(OH)D levels increased in HDVD group vs LDVD group; 
2. PTH decreased in HDVD group but no significant change with 
LDVD; 
3. No change in FLS 
4. IL-17 levels increased in HDVD and LDVD groups ; 
5. No significant differences in relapse rate, EDSS, QoL, serum IL-10 
and IFNγ; 
6. Serum calcium levels remained stable and within normal range in 
both dosage groups 
1. P < 0.001 
2. P = 0.04; P = 0.17 
3. N/A 
4. P = 0.75; P = 0.04 
5. P > 0.05 
6. P = 0.2; P = 0.4 
Vitamin D supplementation was associated with dose -
dependent changes in IL-17 serum levels, while  not 
affecting IFN−β related FLS; vitamin D supplementation 
at the doses used seems safe 
[14] 1. Serum levels of 25(OH)D increased in intervention group and 
edcreased in control; 
2. Serum levels of LAP (TGF-β) increased in intervention and control 
group; 
3. The levels of serum IFN-gamma; IL-17A and in IL-9 increased in 
intervention group 
N/A 
 
1. P = 0.0249; P = 0.173 
3. P=0.0519; P = 0.0666; 
P = 0.0679 
Serum LAP (TGF-β) levels increased significantly in 
people receiving vitamin D; Therefore vitamin D might 
be useful in improving MRI outcomes; The levels of the 
other cytokines did not change significantly in either 
group 
[16] 1. Serum 25(OH)D levels increased in intervention group; 
2. IL-10 levels increased in intervention group; 
3. No significant differences in serum calcium between groups at 
baseline or after 3 months 
1. P < 0.001 
2. P = 0.015 
3. P = 0.980; P = 0.302 
25(OH)D levels increased significantly in those treated 
with vitamin D; IL-10 level increased significantly in the 
intervention group and its anti-inflammatory effect may 
play a role  in improving outcomes in MS 
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[15] 1. Serum 25(OH)D level increased in intervention versus control; 
2. The inflammation marker averages did not differ significantly 
between groups 
1. P < 0.001 
2. P > 0.05 
25(OH)D levels increased significantly in vitamin D 
group versus control; No significant differences for any 
inflammation markers between groups 
[18] 1. Serum 25(OH)D level increased in intervention versus control group; 
2. EDSS scores differ between groups; 
3. Serum levels of IL-17 changed in intervention group; 
4. No significant differences in serum calcium between groups at 
baseline and after 12 weeks 
1. P < 0.001 
2. P = 0.033 
3. P = 0.002 
4. P = 0.980;  
    P = 0.302 
25(OH)D levels increased significantly in people in the 
intervention group; Significant difference in EDSS 
between groups; No difference in IL-17 levels between 
vitamin D and control group 
[17] 1. Serum 25(OH)D level increased in intervention versus control group; 
2. The total amount of lymphocytes are similar between baseline and 
week 48; 
3. The proportion of cells in the immune regulatory cell compartment 
(nTreg, iTreg and Breg) did not change in either group; 
4. IL4+ Th cells decreased in the control but not the intervention group;  
5. T cell cytokine secretion increased (IL5, LAP (TGF-β)) in the control 
but not the intervention group 
1. P < 0.001 
2. P > 0.05 
3. P > 0.05 
4. P = 0.04; P = 0.92 
5. P = 0.02; P < 0.001 
   P = 0.06; P < 0.01 
25(OH)D levels increased significantly in the vitamin D 
group; Supplementation of vitamin D did not result in a 
relative increase in the total amount of lymphocytes 
[13] 1. Serum 25(OH)D level increased in HDVD group vs LDVD; 
2. The proportion of interleukin-17+CD4+ T cells, CD161+CD4+ T cells, 
and effector memory CD4+ T cells, the proportion of central memory 
CD4+ T cells and naive CD4+ T cells increased in HDVD group 
1. P < 0.00001 
2. P = 0.016; P = 0.03; P 
= 0.021; P = 0.018; P = 
0.04 
25(OH)D levels increased significantly in the vitamin D 
group; Vitamin D supplementation exhibited 
immunomodulatory effects including reduction of 
interleukin-17 and decreased the proportion of effector 
memory CD4+ T cells with concomitant increase in 
central memory CD4+ T cells and naive CD4+ T cells; 
10,400 IU daily is safe  and tolerable  
[20] 1. Serum 25(OH)D level significantly increased in intervention group 
vs control; 
2. T2 BOD reduced in intervention group vs control; 
3. Total number of Gd enhancing T1 lesions significantly decreased in 
the intervention group vs control; 
4. Fewer new/enlarging T2 lesions in the intervention group vs control;  
5. Gd enhancing lesion volume decreased in intervention group vs 
control; 
6. MRI activity lower in intervention group vs control; 
7. ARR decreased in intervention group vs control; 
8. EDSS decreased in intervention group vs control; 
9. TTW10 decreased in intervention group vs control; 
10. T25FW decreased in intervention group vs control 
  
1.P < 0.001  
2.P = 0.105 
3.P = 0.004 
   
4. P = 0.286 
5. P = 0.320 
6. P = 0.322 
7. N/A 
8. P = 0.071 
9. P = 0.076 
10. P = 0.932 
Vitamin D3 add on treatment to IFNB reduces MRI T1 
enhancing lesions. Vitamin D supplementation at the 
doses used seems safe. 
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VD, vitamin D group; HDVD, high-dose vitamin D group; LDVD, low-dose vitamin D group; ARR, annualised relapse rate; EDSS, Expande d Disability Status Scale- 
scores range from 0 to 10; MSFC, MS functional composite including (25ft timed walk; 9-hole peg test (9-HPT), paced auditory serial addition test (PASAT)); FSS, 
fatigue severity scale - scores range from 1 (no fatigue) to 7; QoL, quality of life ; FLS, flu-like symptoms; LAP, latency activated peptide, IFNβ, Interferon-β;.T2 BOD 
T25FW TTW10. T2 BOD, T2 burden of disease (BOD) on MRI scans; T25FW, timed 25 foot walk, TTW10, timed 10 foot tandem walk. 
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3.10. Disability 
Five of ten studies reported EDSS score as outcome parameter with only one showing a benefit 
after supplementation with vitamin D. Kampman et al. [19] noted that EDSS score did not differ  
significantly between the vitamin D and placebo group after 96  weeks (P = 0.97). Shaygannejad et al. 
[21] found that EDSS score increased significantly (P < 0.01) in a placebo group from a mean of 1.7 to 
1.94, whereas it did not change in people receiving vitamin D and therefore there was no significant 
difference in scores at the end of the trial between intervention and control groups (P  > 0.05). Also, 
Golan et al. [12]demonstrated that high-dose vitamin D supplementation was not associated with 
reduced disability score with no significant change in EDSS score between two groups (P = 0.26). In 
contrast, Toghianifar et al. [18]showed a significant difference in EDSS scores between people allocated 
to vitamin D group (supplemented with 50,000 IU every five days) and placebo group after 12 weeks 
(P = 0.033) in favour of the vitamin D group, and the baseline vitamin D levels in the participants from 
this study was below the minimum recommendation. Soilu-Hänninen et al., [20]found no significant 
change in EDSS score between two groups (P = 0.071). 
3.11. Safety and Tolerability 
Four of the ten studies in this review determined the effect of high-dose vitamin D 
supplementation among people with MS in terms of safety and tolerability and none of the studies 
reported significant differences between control/placebo and vitamin D groups nor were any of the 
adverse events serious in either group. Shaygannejad et al. [21]showed that vitamin D treatment use 
up to 0.5 μg/day of calcitriol appeared to be safe and well tolerated by those with MS. The adverse 
events noted were mild in severity. The most frequently reported included constipation (n = 6 and n = 
4), dyspepsia (n = 6 and n = 2), fatigue (n = 4 and n = 5), and headache (n = 2 and n = 1) in vitamin D and 
placebo groups, respectively. There were no significant differences in frequency of events between 
people who received vitamin D and those who received placebo. Golan et al. [12] indicated that a dose 
of 4370 IU/day over a 48-week period was safe in people with MS. There were no instances of 
hypercalcemia and no reports on new adverse events that could be vitamin D supplement related.  
Sotirchos et al. [13]found that a dose of 10,400 IU of cholecalciferol per day for 24 weeks was safe and 
tolerable in people with MS, with no serious adverse events. Soilu-Hänninen et al. [20]found no 
significant differences between the treatment arms in any of the other clinical chemistry parameters 
studied. No dose adjustments were necessary. Lack of MxA response (MxA < 50 mg/L) was detected in 
three people in both treatment arms at 12 months. Diarrhoea was a side effect in (n = 5 and n = 2) and 
fever was noted (n = 2 and n = 5) in the vitamin D group and placebo group, respectively. All other 
adverse events occurred in a similar number of participants in both groups. There was one serious 
adverse event in the vitamin D group (erysipelas in the interferon injection site treated with intravenous 
antibiotics in hospital) and two in the placebo group (elective hip surgery and elbow fracture). 
4. Discussion 
This review found some evidence for benefits of vitamin D supplementation, specifically for those 
with serum levels at the lower normal range in people with RRMS. Therefore, baseline serum vitamin 
D levels may be a predictor of improvements in disease pathology from vitamin D supplementation, 
cytokine profile and disability status, but possibly also relapse rate, quality of life, mobility, T2 lesions 
load and new T2 and T1 Gd enhancing lesions. Five out of ten studies showed improvement in: 
ARR(x2), EDSS(x2), IFN-gamma, IL-17A, IL-9, IL 10, 17+CD4+ T cells, CD161+CD4+ T cells, and effector 
memory CD4+ T cells, the proportion of central memory CD4+ T cells and naive CD4+ T, TTW 10, 
T25FW, and MRI brain lesion markers, and these were shown in the intervention group compared with 
the control/placebo group. Another similar review to date differed in that cytokine outcomes were not 
assessed and the effects of baseline Vitamin D levels on outcome measures was not explored[11]. 
McLaughlin et al. [11]found that in higher dose vitamin D arms, there were actually adverse changes 
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in ARR and EDSS and therefore although supplementation may have beneficial effects, there may be 
specific doses that should be considered. Jagannath et al., [22]looked at outcome measures including 
fatigue and HRQOL yet found conflicting results in part due to the heterogeneity of the study designs 
and different doses used. Zheng et al. [23] only looked at changes in ARR and EDSS score, with no 
beneficial effect of vitamin D as an add-on therapy on either outcome. Whilst further research is needed, 
this review highlights that all studies on the topic should include baseline vitamin D as part of the 
assessment. There was also low risk of adverse effects and low risk of bias for all studies and therefore 
the validity can be considered high. This review not only includes a more extensive search strategy and 
evaluates bias and although some of the included studies between reviews are similar, the current 
review is more up to date and encompasses a wider range of symptoms and pathology in MS. 
The present consensus on the use of vitamin D supplementation in the management of MS is based 
on the hypothesis that the serum 25(OH)D is associated with prevalence and severity of the disease 
course in established MS. Therefore, its measurements are undertaken as part of the clinical 
management of MS in order to detect vitamin D insufficiency, correct it with supplementation at 
recommended doses and achieve the beneficial immunological effects [4]. All but one study assessed 
levels of serum 25(OH) and all reported a significant increase in 25(OH)D levels following vitamin D 
supplementation. However, the increase in 25(OH)D levels did not appear to affect all MS-related 
outcomes in the reviewed studies. If participants had 25(OH-D) levels at the lower end of normal at 
baseline, a high dose vitamin D supplement intervention may contribute to bettering of physiological 
mechanisms and resulting symptoms, yet if baseline levels are at the higher end of normal (i.e. 50 
nmol/l) then further benefits may not be experienced. In the study by Ashtari et al [16]and Sotirchos et 
al. [13]participants had levels towards the low er end of normal thereby possibly resulting in the 
resulting significant benefit in IL-10 and a variety of mechanistic improvements, respectively. 
Toghianifar et al. [18]found a resulting improvement in EDSS score which wasn’t seen in other studies 
in this review, and again the participants in this study had baseline 25(OH-D) levels at the lower end 
of normal. All other studies had participants with higher baseline levels and also contained more varied 
results, with fewer significant changes between groups. 
When looking at the immunological outcomes, the reviewed studies reported mixed effects of 
vitamin D supplementation. Vitamin D plays an important role in immune system function by reducing 
the production of proinflammatory cytokines and inducing the production of anti -inflammatory 
cytokines [24]. Only two selected studies detected a significant increase in levels of anti-inflammatory 
cytokines in the vitamin D group and therefore findings of studies evaluating the effect of the vitamin 
D supplementation on the reduction of proinflammatory cytokines are conflicting. Th e heterogeneity 
of intervention effects on immunologic activity reported in reviewed trials may be explained by 
considering possible confounding parameters including dosage and duration of administering vitamin 
D supplementation and supports previous findings demonstrating that a more pronounced 
immunologic impact of vitamin D supplementation was reported in vitamin D doses up to 40,000 IU 
per day [24]. Moreover, the fact that almost all participants in above trials were treated by 
immunomodulatory treatment, which mostly comprised interferon-beta (IFN-β) therapy (Table 6), may 
have altered the cytokine responses to vitamin D and/ or made it more difficult to determine the isolated 
effect of vitamin D supplementation and therefore beneficial effects of an increase in 25(OH)D on the 
outcome markers examined may be undetectable due to the strong immunomodulatory effect of IFN -
β[25]. It has been suggested that type of therapy a person receives may influence the observed impact 
of vitamin D supplementation[26]. Notwithstanding, some studies demonstrated a synergistic 
immunomodulatory effect of IFN-β and vitamin D that induce favourable alterations in the 
inflammatory profile in people with MS [12] [13]. Also, when considering the study conducted by Golan 
et al. [12] and Sotirchos et al. [13]including low-dose of vitamin D as a comparator may reduce the 
ability to notice minor differences compared to the use of a placebo. Although results of studies 
evaluating changes in immunological profiles in people with MS are not consistent, they suggest that 
supplementation of vitamin D promotes the immune regulatory cytokines and reduces 
proinflammatory immune parameters. Only two studies assessed changes in functional measures, and 
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although the relationship betw een vitamin D and improved outcomes in participants with MS was 
found by Soilu-Hänninen et al. [20] T1 enhancing lesions and trends in MRI burden of disease (BOD) 
and EDSS, there is currently not enough clinical data to suggest the effectiveness of the treatment.  
The correlation between 25(OH)D and reduced relapse rates have been found in several 
prospective cohort studies. The study by Laursen et al.[27]reported that the increase in serum 25(OH)D 
level was associated with decreases in ARR in those with RRMS. Those results were in line with a 
previously conducted cohort study by Simpson et al. [28]  investigating a role of 25(OH)D levels in 
modulating MS clinical course in 145 participants with RRMS that suggests a benefit of serum 25(OH)D 
level on relapse rates at levels approximately 100 nmol/L. However, three reviewed studies evaluating 
vitamin D supplementation in management of MS have demonstrated no effect of 25(OH)D on relapse 
rate. Although mean serum 25(OH)D level more than doubled in the high-dose intervention groups in 
the study by Kampman et al. [19], Soilu-Hänninen et al. [20]  and Golan et al. [12], they found no 
significant difference in ARR between groups at the end of the study period (96 and 48 weeks, 
respectively). Also, Shaygannejad et al. [21]failed to detect significant difference in relapse rate between 
the intervention and control groups at 48 weeks although the relapse rate decreased significantly in the 
vitamin D group. One possible explanation for the discrepancies between findings of ab ove trials and 
previous studies may be related to eligibility criteria for included participants, vitamin D dosage and 
form, and duration of the intervention. Other explanations for the results in these RCTs may be related 
to the low ARR at baseline which could contribute to the absence of significant effects. In addition, the 
study conducted by Kampman et al. [19]enabled participants to continue the use of vitamin D 
supplements they used prior the study, which contributed to comparatively high 25(OH)D 
concentration in the placebo group and a difference between groups could not be detected. 
High levels of 25(OH)D (>50 nmol/L) have also been shown to be associated with reduced 
disability measured by EDSS in MS [29]. Based on the evidence contained in this review, the effect of 
vitamin D supplementation on reducing disability remains unclear. Kampman et al.  [19], Soilu-
Hänninen et al. [20], Shaygannejad et al. [21]and Golan et al. [12]reported no significant change in EDSS 
score between the intervention and control groups. Conversely, a trial conducted by Toghia nifar et al. 
[18] demonstrated a significant positive difference in EDSS scores between participants allocated to 
vitamin D vs placebo groups. Although the inclusion criteria were limited to participants with EDSS  < 
4 that indicate absence of observations in the higher EDSS range, a dose of 50,000 IU vitamin D every 
five days after 12 weeks was associated with less neurological disability. 
Additionally, four studies looked at the safety and tolerability of high dosing regimens of vitamin 
D supplementation through the duration of the intervention. Through the studies observed it could be 
clearly recognised that vitamin D treatments were relatively safe, well-tolerated, and no concerning 
adverse events such as hypercalcemia and hypercalciuria triggered by high  doses of vitamin D were 
reported. This is consistent with findings from previous studies that demonstrated safety of high -dose 
vitamin D below the daily limit of 10,000 IU in MS [30]. All other adverse events occurred in a similar 
number of participants in both groups for all studies. There was one serious adverse event in the 
vitamin D group (erysipelas in the interferon injection site treated with intravenous antibiotics in 
hospital) and two in the placebo group (elective hip surgery and elbow fracture). What can be 
concluded from this systematic review is that it seems participants in all studies adhered to the vitamin 
D interventions due to a resulting increase in serum levels in all studies (n = 9), and therefore the safety 
and tolerability of supplementation at high doses can be considered a reliable outcome. 
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Table 6. Dose of vitamin D and concomitant immunomodulatory therapy used in selected studies. 
Study High-Dose of Vitamin D 
Low-Dose of 
Vitamin D 
Placebo Concomitant Immunomodulatory Therapy and Vitamin D/Calcium Supplements 
[19] 20,000 IU of vitamin D3 per week ✗ ✔ 500 mg/d calcium; no restrictions on vitamin D supplements 
[21] 
0.25 μg/d of calcitriol for 2 weeks and 
then 0.5 μg/d 
✗ ✔ IFNβ (86.0% of participants), statins (10.0%), or immunosuppressive drugs (4.0%) 
[12] 4370 IU/d of vitamin D3 
800 IU/d of 
vitamin D3 
✗ IFNβ  
[14] 20,000 IU of vitamin D3 per week ✗ ✔ IFNβ  
[16] 50,000 IU of vitamin D3 every 5days ✗ ✔ IFNβ; interferon-β; participants were not allowed to take any other vitamin D supplements; 
[15] 20,000 IU vitamin D3 per week ✗ ✔ 
calcium supplementation (500 mg/d); no restrictions on regular vitamin D supplementation or 
immunomodulatory treatment (i.e ., IFN-b, glatiramer acetate, or natalizumab) 
[18] 50,000 IU of vitamin D3 every 5days ✗ ✔ IFNβ  
[17] 
7000 IU/d of vitamin D3 for 4 weeks, 
followed by 14,000 IU/d of vitamin D3; 
✗ ✔ IFNβ-1a 
[13] 10,400 IU/d of vitamin D3 
400 IU/d of 
vitamin D3 
✗ 
89% of participants received immunomodulatory therapy; multivitamin containing 400 IU of 
D3 and 1000 mg/d of calcium 
[20] 20,000 IU of vitamin D3 per week ✗ ✔ IFNβ-1b 
IFNβ, Interferon-β. 
Int. J. Mol. Sci. 2019, 20, 1301 17 of 19 
 
5. Limitations 
As the reviewed studies took place in different geographic locations, sun exposure was different 
amongst groups and makes the comparison less reliable. Of note, all studies recruited participants 
with RRMS in order to ensure the homogeneity of the treatment groups in terms of the disease course 
and mechanisms. However, it has been demonstrated that immunomodulatory strategies employed 
for RRMS are not considered effective when applied in PPMS, suggesting cause for caution when 
generalising results to the greater MS population. Disease duration before the commencement of 
treatment varied between 4 months to 27 years and the time at which vitamin D intervention is 
implemented may affect the effectiveness of the treatment. Some studies assessed clin ical endpoints 
such as relapse rates, disability scores, and physical changes, while some assessed only biomarker 
outcomes. As a result, heterogeneity of outcomes may have affected end-line comparisons and made 
doing a meta-analysis unfeasible. 
6. Conclusion 
Vitamin D supplementation may be a promising treatment and represents a reliable background 
for further exploration of potential benefit for MS regarding clinical improvements. A high dose 
vitamin D supplement intervention may contribute to bettering of physiological mechanisms if 
baseline plasma levels are at the lower end of normal. Further research addressing the matters 
discussed above is required before a causal association between vitamin D supplementation and 
disease activity in people with MS can be established. 
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